MED
Medifast, Inc. (MED) Management Analysis (2026)
Overall Score
Leadership Execution
Management is operating with a strong liquidity cushion, as the current ratio is 4.86 and cash per share is 15.25.
Execution remains challenged by weak profitability, with TTM operating margin at -5.46% and net margin at -8.08%.
Capital Allocation
Capital allocation appears conservative, with debt-to-equity at 0.14 and debt-to-assets at 0.11.
Free cash flow remains positive but modest relative to valuation, with free cash flow yield at 2.85% and price-to-free-cash-flow at 35.11.
Governance Incentives
No fresh news or metrics indicate a material change in governance or incentive alignment this month.
The balance sheet remains manageable, with net debt-to-EBITDA at 12.40 but strong current liquidity offsetting near-term pressure.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Medifast, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.